Published in Pharma Investments, Ventures and Law Weekly, July 25th, 2004
The phase II clinical trial is expected to enroll up to 30 patients with prostate cancer. Patients are expected to receive four biweekly doses of 1, 5, or 10 mg/kg of MDX-070 and will be assessed for tumor response based on objective tumor response and decrease in prostate specific antigen serum levels.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly